Angle gains on breakthrough in cancer diagnostic technology
14th Jan 2013 09:46
Angle advanced more than 90 per cent Monday after the medtech company announced a major breakthrough in its cancer diagnostic product Parsotix. The AIM listed company said it had edged further in the development of Parsortix, a non-invasive technology which captures and counts rare circulating tu
Read moreSharp drop in Angle shares following business update
10th Dec 2012 15:01
AIM-listed medtech company Angle revealed that Origio, a partner involved in the development of a technology patented as EmbryoSure, has decided to cease EmbryoSure studies in a business update on Monday. EmbryoSure is a technology being developed to assess the viability of embryos for transfer in
Read moreSmall caps round-up: Cyan, Aer Lingus, Mobile Tornado ...
7th Jun 2012 13:59
Cyan Holdings, the wireless solutions company, has revealed that three more Cyan partners have received requests from the Tamil Nadu Electricity Board (TNEB) Automatic Meter Reading tender to proceed with installation and commissioning of 500 unit pilots within the next 25 days. The news follows Cya
Read moreSmall caps round-up: Westminster Group, Angle, Asterand
30th Apr 2012 08:47
Defence technology firm Westminster Group said its investment in a West African airport was looking promising and that an initial aggregate $150m revenue forecast could be achieved by the contract's eight year break point rather than the full contract term of 15 years. "Should that be the case, the
Read moreSmall caps round up: Intandem, Digital Learning, Hornby ...
23rd Apr 2012 14:31
Intandem Films, the London and Los Angeles based international film group, will co-produce 10 Things I Hate About Life, and sell the film internationally. The company will also distribute the film in the UK. The script has been written and the film will be directed by Gil Junger, the director of the
Read moreAngle success with ovarian cancer
17th Apr 2012 10:40
Shares in technology investment firm Angle rose on Tuesday after it said its Parsortix cell separation device had passed an important milestone. The firm said that the device could now capture ovarian cancer cells, creating the possibility of developing an effective, non-invasive screening techniqu
Read moreSmall caps round-up: Top Level Domain, Transense, SkyePharma
11th Apr 2012 09:46
Top Level Domain Holdings, which operates generic top-level domains, has revealed that is wholly-owned subsidiary, Minds and Machines, has been appointed by Dot London Domains (DLD), the official promotional organisation for London, to assist with DLD's application for the position of registry opera
Read moreSmall caps round-up: HMV, Corero, ANGLE ...
15th Mar 2012 12:06
HMV Group, the struggling entertainment media seller, has confirmed that it is still pondering what to do with its live music business. HMV added that a number of parties have indicated an interest in acquiring the business. There has been press speculation recently about who might be interested in
Read moreAngle raises £1.2m, swings to a half-year loss
26th Jan 2012 13:10
Technology investment company ANGLE has raised £1.2m through a fundraising on the same that it revealed it had swung to a loss in the first half ended October 31st. The firm said on Thursday that investors will acquire up to 1,715,717 new ordinary shares in the company at a price of 70p per shar
Read moreAngle makes important step in cancer technology
23rd Jan 2012 14:25
Angle's 90%-owned portfolio company, Parsortix, which specialises in medical diagnostics, has used its cell separation device to successfully capture circulating tumour cells (CTCs) in cancer patient blood. The Parsortix separation technology has already been used to capture cultured breast cancer
Read moreAngle shares storm north on Parsortix lung cancer result
16th Dec 2011 10:37
Angle, the technology investment company, saw its share price go vertical on Friday morning on the back of success at one its investments, Parsortix. Parsortix, which specialises in medical diagnostics, has confirmed its cell separation device can "capture cultured lung cancer cells". This comes af
Read moreAngle reports further delays on IVF product
16th Nov 2011 16:00
Shares in Angle, the Surrey-based technology investment firm, fell today after it reported delays to its IVF product EmbryoSure. The embryo viability product is being developed by Novocellus, which is 82% owned by Angle. The firm had already said the trial of EmbryoSure was delayed, but today adde
Read moreAngle prostate cancer test sees shares rocket
11th Nov 2011 08:21
Angle, the Surrey-based technology investment firm, has seen its share price rocket nearly 15% on news one of its divisions has found a new way to detect prostate cancer. Parsortix, which is 90% owned by Angle, claims its "separation technology" can capture prostate cancer cells added to blood. T
Read moreAngle buys 90% stake in cancer diagnostic firm
5th Oct 2011 14:01
Angle has increased its stake in its subsidiary, Parsotix, to 90% following the success of the cancer diagnostic firm's cell separation device. The fund the move, Angle raised £1.25m in July, 80% of which has been allocated to Parsortix to fund the definitive validation of its initial findings, wh
Read moreAngle announces new cancer detection device
28th Sep 2011 08:38
Technology firm Angle has announced that Parsortix, its 85% owned portfolio company which specialises in medical diagnostics, has achieved a major milestone by validating that its cell separation device can capture cancer cells added to blood. Parsortix's patented cell separation device can be used
Read more